Six of eight patients (75%) with HER2-positive rectal adenocarcinoma responded to trastuzumab and tucatinib plus chemotherapy ...
New research contributes to identifying which breast lesions will progress to cancer, thus helping avoid overtreatment ...
Direct injection of a low dose of the immune checkpoint inhibitor nivolumab into precancerous oral lesions significantly reduced lesion size and risk of cancer progression, sparing most patients from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results